Evidence map›Paper›PMID 16982933›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2006

An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions.

Zeyu Xiong, Enli Liu, Yan Yan, Richard T Silver, Fan Yang, Irene H Chen, Yangyang Chen, Srdan Verstovsek, Hong Wang, Josef Prchal and 1 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05535764 (Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05535764 phase1recruitingnot on this mapstarted 2023, after this paper: background citation

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)

TypeinterventionalSponsorUniversity of UtahRan2023 to 2028Enrolled18ConditionsMyelofibrosisArmsPegylated interferon alpha2a
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Mammalian Polycistronic mRNAs and Disease.Trends in genetics : TIG · 2017
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. IRES Trans-Acting Factors, Key Actors of the Stress Response.International journal of molecular sciences · 2019
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zeyu XiongDepartment of Pharmacology, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, PA 19140, USA.
Enli Liu
Yan Yan
Richard T Silver
Fan Yang
Irene H Chen
Yangyang Chen
Srdan Verstovsek
Hong Wang
Josef Prchal
Xiao-Feng Yang
Temple University · USBaylor College of Medicine · USNewYork–Presbyterian Hospital · USThe University of Texas MD Anderson Cancer Center · US

Funding

Survival of CD4+CD25+ Regulatory T CellsK08AI054514 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAO-FENG · 2003 to 2007
$589k
NIAID NIH HHS AI 054514NIAID NIH HHS K08 AI054514
6 · The paper itself

Abstract

Self-tumor Ags that elicit antitumor immune responses in responses to IFN-alpha stimulation remain poorly defined. We screened a human testis cDNA library with sera from three polycythemia vera patients who responded to IFN-alpha and identified a novel Ag, MPD6. MPD6 belongs to the group of cryptic Ags without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'-untranslated region of myotrophin mRNA. MPD6 elicits IgG Ab responses in a subset of polycythemia vera patients, as well as patients with chronic myelogenous leukemia and prostate cancer, suggesting that it is broadly immunogenic. The expression of myotrophin-MPD6 transcripts was up-regulated in some tumor cells, but only slightly increased in K562 cells in response to IFN-alpha treatment. By using bicistronic reporter constructs, we showed that the translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES-mediated translation, but not myotrophin-MPD6 transcription, was significantly up-regulated in response to IFN-alpha stimulation. These findings demonstrate that a novel IRES-mediated mechanism may be responsible for the translation of unconventional self-Ag MPD6 in responsive to IFN-alpha stimulation. The eliciting antitumor immune response against unconventional Ag MPD6 in patients with myeloproliferative diseases suggests MPD6 as a potential target of novel immunotherapy.

Indexed as

Protein BiosynthesisAmino Acid SequenceAntigens, NeoplasmBlotting, NorthernBlotting, WesternEnzyme-Linked Immunosorbent AssayGene LibraryHumansIntercellular Signaling Peptides and ProteinsInterferon-gammaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMolecular Sequence DataPolycythemia VeraProstatic NeoplasmsProtein Structure, SecondaryAntigens, NeoplasmIntercellular Signaling Peptides and ProteinsInterferon-gammamyotrophinRNA, Messenger

Identifiers

PMID16982933
PMCPMC3902139
OpenAlexW4237775567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.